Evofem Biosciences Inc
Change company Symbol lookup
Select an option...
EVFM Evofem Biosciences Inc
RNWWW ReNew Energy Global Equity Warrant Exp 23rd Aug 2026 *W EXP 08/23/2026
RVPH Reviva Pharmaceuticals Holdings, Inc.
TPR Tapestry Inc
BGRY Berkshire Grey Inc
BKNG Booking Holdings Inc
UHT Universal Health Realty Income Trust
BBVA Banco Bilbao Vizcaya Argentaria SA
RILY B Riley Financial Inc
WTS Watts Water Technologies Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. It also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.

Closing Price
$0.048
Day's Change
-0.001 (-2.04%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.05
Day's Low
0.0471
Volume
(Light)
Volume:
1,923,446

10-day average volume:
3,536,102
1,923,446

Display:

Providers:

UpdateCancel
6 providers
January 12, 2023
Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)

Phexxi is the first and only hormone-free contraceptive in the Favor product portfolio -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that female telehealth leader Favor is now a specialty pharmacy provider of Phexxi(R)(lactic acid...(PR Newswire)

January 10, 2023
Costco Adds Phexxi(R) to Member Prescription Program

Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that Phexxi(R)(lactic acid, citric acid, potassium bitartrate) has been added to the Costco Member Prescription Program,giving millions of additional women access to this innovative hormone-free...(PR Newswire)

December 29, 2022
OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022

Evofem Biosciences, Inc. (OTCQB: EVFM)today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the "10-Q"). Previously, the OTC Markets...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.